Mayne Pharma Group Limited (MAYNF) Stock Analysis

Mayne Pharma Group Limited (MAYNF) Healthcare & Pipeline Overview

Mayne Pharma Group Limited, based in Australia, develops, manufactures, and markets pharmaceutical products globally. With a focus on oral drug delivery and specialty areas like dermatology and women's health, the company operates through four segments, including contract services and international distribution, facing competition in the general drug manufacturing sector.

What Is the Investment Thesis for MAYNF?

Mayne Pharma Group Limited presents a complex investment case. With a market capitalization of $191M and a negative P/E ratio of -2.24, the company's profitability is a concern, evidenced by a negative profit margin of -20.4%. However, a gross margin of 54.8% indicates potential in operational efficiency. Key value drivers include the Metrics Contract Services segment and international expansion. Growth catalysts involve new product launches and strategic partnerships. Potential risks include regulatory challenges, competition from generic manufacturers, and the company's ability to achieve sustained profitability. Investors should closely monitor the company's financial performance and strategic initiatives.

Based on FMP financials and quantitative analysis

MAYNF Key Highlights

Market capitalization of $191M indicates its size relative to competitors.

• Negative P/E ratio of -2.24 reflects current unprofitability.
• Profit margin of -20.4% highlights operational challenges.
• Gross margin of 54.8% suggests potential for profitability with improved cost management.
• Beta of 0.98 indicates volatility similar to the overall market.

Who Are MAYNF's Competitors?

MAYNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MAYNF's Key Strengths?

Diverse product portfolio across branded and generic pharmaceuticals.

• Global presence with operations in multiple regions.
• Established manufacturing capabilities.
• Contract services segment provides a stable revenue stream.

What Are MAYNF's Weaknesses?

Negative profit margin indicates financial challenges.

• High debt levels may constrain growth opportunities.
• Dependence on key products and markets.
• Exposure to regulatory risks and pricing pressures.

What Could Drive MAYNF Stock Higher?

Potential new product launches in dermatology and women's health.

• Expansion of Metrics Contract Services through new partnerships.
• Geographic expansion into emerging markets.
• Regulatory approvals for key pipeline products.
• Cost optimization initiatives to improve profitability.

What Are the Key Risks for MAYNF?

Financial-distress signal — its Altman Z-Score of -0.56 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-23.0%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Intense competition from generic and branded pharmaceutical companies.
• Regulatory changes and pricing pressures.
• Product liability claims and recalls.
• Negative profit margin indicates financial challenges.
• High debt levels may constrain growth opportunities.

What Are the Growth Opportunities for MAYNF?

• Expansion of Metrics Contract Services: Mayne Pharma can leverage its Metrics Contract Services segment to drive growth by securing additional contracts with pharmaceutical companies seeking development, manufacturing, and analytical services. The global pharmaceutical contract manufacturing market is projected to reach $227.7 billion by 2028, presenting a significant opportunity for Mayne Pharma to increase its market share. This expansion can be achieved through targeted marketing and strategic partnerships.
• New Product Development and Launches: Mayne Pharma can invest in research and development to create and launch new branded and generic pharmaceutical products. Focusing on therapeutic areas with unmet needs, such as dermatology and women's health, can drive revenue growth. Successful product launches require regulatory approvals and effective marketing strategies. The timeline for new product development varies depending on the complexity of the drug and regulatory requirements.
• Geographic Expansion: Mayne Pharma can expand its presence in existing markets and enter new geographic regions to increase its customer base and revenue streams. Focusing on emerging markets with growing healthcare expenditures can provide significant growth opportunities. This expansion requires careful market analysis, regulatory compliance, and strategic partnerships with local distributors. The timeline for geographic expansion depends on the specific market and regulatory environment.
• Strategic Acquisitions: Mayne Pharma can pursue strategic acquisitions to expand its product portfolio, geographic reach, and manufacturing capabilities. Acquiring companies with complementary products or technologies can create synergies and drive revenue growth. Successful acquisitions require careful due diligence and integration planning. The timeline for acquisitions depends on the size and complexity of the target company.
• Partnerships and Collaborations: Mayne Pharma can form partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to develop and commercialize new products and technologies. These partnerships can provide access to new markets, expertise, and resources. Successful partnerships require clear agreements and effective communication. The timeline for partnerships depends on the specific project and objectives.

What Are MAYNF's Competitive Advantages?

• Proprietary oral drug delivery systems offer a technological advantage.
• Established manufacturing capabilities provide a barrier to entry.
• Global distribution network enables access to multiple markets.
• Contract services segment provides a diversified revenue stream.

What Does MAYNF Do?

Mayne Pharma Group Limited, originally Halcygen Pharmaceuticals Limited, was founded in 2005 and rebranded in 2010. Headquartered in Salisbury South, Australia, the company operates as a specialty pharmaceutical manufacturer and distributor with a global reach, including Australia, New Zealand, the United States, Canada, Europe, and Asia. The company's business is divided into four key segments: Metrics Contract Services, which provides pharmaceutical development, manufacturing, and analytical services; International, which handles distribution in various global markets; Branded Products, focusing on proprietary pharmaceuticals; and Portfolio Products, encompassing a range of established medications. Mayne Pharma specializes in oral drug delivery systems and offers a diverse portfolio of generic and branded products in therapeutic areas such as dermatology, women's health, and infectious diseases. The company aims to leverage its manufacturing capabilities and global presence to deliver pharmaceutical solutions to patients and healthcare providers.

What Products and Services Does MAYNF Offer?

• Manufactures and sells branded pharmaceutical products.
• Manufactures and sells generic pharmaceutical products.
• Provides oral drug delivery systems.
• Offers contract pharmaceutical development services.
• Offers contract pharmaceutical manufacturing services.
• Provides contract pharmaceutical analytical services.
• Distributes specialty pharmaceutical products in dermatology.
• Distributes specialty pharmaceutical products in women's health and infectious diseases.

How Does MAYNF Make Money?

• Develops and manufactures generic and branded pharmaceuticals.
• Generates revenue through product sales in various geographic markets.
• Provides contract services to third-party pharmaceutical companies.
• Focuses on specialty therapeutic areas such as dermatology and women's health.

What Industry Does MAYNF Operate In?

Mayne Pharma operates within the competitive drug manufacturing industry, facing pressure from both generic and branded pharmaceutical companies. The industry is characterized by stringent regulatory requirements, intense research and development, and pricing pressures. Market trends include increasing demand for generic drugs, advancements in drug delivery technologies, and a growing focus on specialty pharmaceuticals. Mayne Pharma's focus on oral drug delivery systems and contract services positions it to capitalize on these trends, but it must navigate the competitive landscape and regulatory hurdles to achieve sustainable growth.

Who Are MAYNF's Key Customers?

• Patients who use their branded and generic pharmaceutical products.
• Hospitals and clinics that prescribe or administer their products.
• Pharmacies that dispense their medications.
• Third-party pharmaceutical companies utilizing their contract services.

Mayne Pharma Group Limited (MAYNF) Valuation Context

Valued at $191M, MAYNF is classified as a micro-cap stock.

MAYNF Revenue & Earnings Trend

In Q4 FY2026, MAYNF generated $122.9M in top-line revenue, marking a sequential decrease of 19.2%. The company recorded net income of $28.2M, with diluted EPS of $0.30. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MAYNF averaged $-0.17 in diluted EPS.

Company Profile

Mayne Pharma Group Limited operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Salisbury South, AU. The company is led by CEO Aaron Gray. MAYNF has traded publicly since 2013.

Return on equity for Mayne Pharma Group Limited stands at -23.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -35.2%, the inverse of the P/E and a quick read on earnings relative to price.

Mayne Pharma Group Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.56 places it in the distress zone, a signal of elevated financial risk.

Mayne Pharma Group Limited has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 2019.2% below estimates on average.

MAYNF Financials

MAYNF Latest News

MAYNF Analyst Consensus

MAYNF MoonshotScore

What Investors Ask About Mayne Pharma Group Limited (MAYNF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources